Suboptimal Clinical and Quality of Life Outcomes in Patients with Psoriasis Undertreated with Oral Therapies: International Physician and Patient Survey

[1]  M. Lebwohl,et al.  Evolution of Patient Perceptions of Psoriatic Disease: Results from the Understanding Psoriatic Disease Leveraging Insights for Treatment (UPLIFT) Survey , 2021, Dermatology and Therapy.

[2]  J. Curtis,et al.  Real-world switch patterns and healthcare costs in biologic-naive psoriasis patients initiating apremilast or biologics. , 2020, Journal of comparative effectiveness research.

[3]  Jashin J. Wu,et al.  Treatment patterns and healthcare costs among biologic-naive patients initiating apremilast or biologics for the treatment of psoriatic arthritis: results from a US claims analysis , 2019, Current medical research and opinion.

[4]  Ruilian Li,et al.  Short-Term Efficacy and Safety of IL-17, IL-12/23, and IL-23 Inhibitors Brodalumab, Secukinumab, Ixekizumab, Ustekinumab, Guselkumab, Tildrakizumab, and Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trial , 2019, Journal of immunology research.

[5]  B. Devine,et al.  Psoriasis treatment patterns: a retrospective claims study , 2019, Current medical research and opinion.

[6]  B. Strober,et al.  Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. , 2019, Journal of the American Academy of Dermatology.

[7]  R. Vangipuram,et al.  Apremilast for the management of moderate to severe plaque psoriasis , 2017, Expert review of clinical pharmacology.

[8]  A. Armstrong,et al.  Under-Treatment of Patients with Moderate to Severe Psoriasis in the United States: Analysis of Medication Usage with Health Plan Data , 2016, Dermatology and Therapy.

[9]  J. Piercy,et al.  Evidence for validity of a national physician and patient-reported, cross-sectional survey in China and UK: the Disease Specific Programme , 2016, BMJ Open.

[10]  T. Brown,et al.  A multicenter, non-interventional study to evaluate patient-reported experiences of living with psoriasis , 2015, The Journal of dermatological treatment.

[11]  P. Gisondi,et al.  European S3‐Guidelines on the systemic treatment of psoriasis vulgaris – Update 2015 – Short version – EDF in cooperation with EADV and IPC , 2015, Journal of the European Academy of Dermatology and Venereology : JEADV.

[12]  M. Lebwohl,et al.  Undertreatment, treatment trends, and treatment dissatisfaction among patients with psoriasis and psoriatic arthritis in the United States: findings from the National Psoriasis Foundation surveys, 2003-2011. , 2013, JAMA dermatology.

[13]  K. Kragballe,et al.  Treatment patterns, treatment satisfaction, severity of disease problems, and quality of life in patients with psoriasis in three Nordic countries. , 2013, Acta dermato-venereologica.

[14]  A. Armstrong,et al.  Quality of Life and Work Productivity Impairment among Psoriasis Patients: Findings from the National Psoriasis Foundation Survey Data 2003–2011 , 2012, PloS one.

[15]  A. Gottlieb,et al.  Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies. , 2009, Journal of the American Academy of Dermatology.

[16]  J. Piercy,et al.  Real-world physician and patient behaviour across countries: Disease-Specific Programmes – a means to understand , 2008, Current medical research and opinion.

[17]  A. Finlay,et al.  Dermatology Life Quality Index (DLQI)—a simple practical measure for routine clinical use , 1994, Clinical and experimental dermatology.